p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo

M. Cardinali, J. Jakus, S. Shah, J. F. Ensley, K. C. Robbins, William Andrew Yeudall

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

The excessive proliferation exhibited by cancer cells is frequently a result of their failure to adequately regulate cell cycle progression. In the present study, we developed a xenograft model of oral cancer in athymic mice, using squamous carcinoma cell lines and examined the ability of the cyclin- dependent kinase inhibitor p21 (WAF1/Cip1) to retard tumour growth in vivo, using a retroviral delivery system. Human p21 cDNA was cloned by polymerase chain reaction, expressed, and the encoded protein shown to have biological activity in in vitro kinase assays. Amphotropic retrovirus cultures which expressed recombinant p21 were generated and used to treat established squamous cell carcinoma xenografts. Two weeks following onset of treatment, tumours injected with p21 virus producer cells showed a reduction in size between 3- and 10-fold compared with tumours which received control cells which produced control virus alone. The data indicate that recombinant p21 may be of future use for therapeutic intervention in oral cancer.

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalOral Oncology
Volume34
Issue number3
DOIs
StatePublished - May 1 1998
Externally publishedYes

Keywords

  • Cell cycle
  • Cip1
  • Gene therapy
  • Oral cancer
  • P21
  • Tumour suppressor
  • WAF1
  • sdil

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo'. Together they form a unique fingerprint.

  • Cite this